skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon


Ray Barlow, CEO of e-Therapeutics, talks to Scrip on the sidelines of the BIO-Europe partnering conference in Berlin, Germany, about network-driven discovery and its use by today's innovative pharma sector.






CEO of e-Therapeutics PLC, Ray Barlow, talks about working backwards to solve drug discovery and development problems, starting with the end target in mind and then thinking about how to apply new technologies to reach the bull's eye.



E-therapeutics' technology works by combining biological expertise and a powerful computer-based platform to create and analyze network models of disease to identify likely proteins that could be disrupted to treat a disease. It uses mathematical and data analysis techniques to augment and interrogate the vast amount of biological information currently available in both public and private databases.



With its technology, e-Therapeutics aims to shorten discovery times and reduce drug development costs.



Scrip & EBD Group